Ignite Creation Date:
2024-05-06 @ 7:46 PM
Last Modification Date:
2024-10-26 @ 3:13 PM
Study NCT ID:
NCT06130124
Status:
RECRUITING
Last Update Posted:
2023-11-14
First Post:
2023-11-08
Brief Title:
S-amlodipine in Essential HypertensIon and Assessment of Blood Pressure Targets Achievement
Sponsor:
Hanlim Pharm Co Ltd
Organization:
Hanlim Pharm Co Ltd
Study Overview
Official Title:
S-amlodipine in Essential HypertensIon and Assessment of Blood Pressure Targets Achievement According to 2022 KSHKorean Society of Hypertension Guidelines SHIFT
Status:
RECRUITING
Status Verified Date:
2023-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Evaluate the ratio of patients whose blood pressure measured at 6 months from the baseline was confirmed to be within the target blood pressure range according to the 2022 hypertension treatment guidelines for essential hypertension patients who received the study drug
Detailed Description:
Primary purpose
Evaluate the ratio of patients whose blood pressure measured at 6 months from the baseline was confirmed to be within the target blood pressure range according to the 2022 hypertension treatment guidelines for essential hypertension patients who received the study drug
Secondary purpose
1 Evaluate the efficacy by comparing the change in blood pressure for each drug pattern monotherapy or combination therapy at 6 months after administration of the drug to be studied in patients with essential hypertension
2 Evaluate the safety by checking the incidence of adverse events after administration of the drug to be studied in patients with essential hypertension
3 Evaluate the safety by checking the peripheral edema incidence rate after administration of the drug to be studied in patients with essential hypertension
4 Evaluate the safety by checking the headache incidence rate after administration of the drug to be studied in patients with essential hypertension
Evaluate the ratio of patients whose blood pressure measured at 6 months from the baseline was confirmed to be within the target blood pressure range according to the 2022 hypertension treatment guidelines for essential hypertension patients who received the study drug
Secondary purpose
1 Evaluate the efficacy by comparing the change in blood pressure for each drug pattern monotherapy or combination therapy at 6 months after administration of the drug to be studied in patients with essential hypertension
2 Evaluate the safety by checking the incidence of adverse events after administration of the drug to be studied in patients with essential hypertension
3 Evaluate the safety by checking the peripheral edema incidence rate after administration of the drug to be studied in patients with essential hypertension
4 Evaluate the safety by checking the headache incidence rate after administration of the drug to be studied in patients with essential hypertension
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None